A Time to Buy


Caution reigns supreme in boardrooms when it comes to giving the green light to an acquisition.

In this article, John Allbrook, Kevin Appleton, Roger Buckley, Don Elgie, Aleen Gulvanessian, Colin Mayer and Siva Shankar identify the key points to address when buying another business.
 












Share this with your Community



Contributors
Aleen Gulvanessian
Partner
Eversheds, London, United Kingdom
Colin Mayer
Emeritus Professor
Said Business School, Oxford University
Don Elgie
Former CEO
Creston
John Allbrook
Former Board Mentor
Criticaleye
Kevin Appleton
Non Executive Director
Ramirent
Roger Buckley
Partner – Birmingham
BDO
Siva Shankar
Chief Financial Officer
The Training Room


Click here to download this insight

DOWNLOAD INSIGHT



Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.


Click here to download this insight

Employee Happiness in the Age of AI

In this report, Criticaleye Partner AlixPartners and Darwin X argue that retail sits at the bottom of the employee happiness ranking across all major industries, and that closing this gap has become a strategic imper...


Click here to download this insight

VIEWPOINTS | Making the Leap from CPO to NED

Tea Colaianni MBE's career began in Brussels as a lawyer before deciding  she wanted to be in the driving seat. "I didn't want just to be advising companies on what to do: I wanted to do stuff,...


The Future of Executive Leadership and High Performance

Andrew Darfoor, SID, Post Office & Board Mentor at Criticaleye, and Jodene Young, Chief People Officer at the National Physical Laboratory (NPL), join Bridgette Hall, Senior Editor at Criticaleye, for a discussio...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 237




Global Payments Stream Aldermore Group Mayborn Group Southern Water Drax Group plc E.ON UK LACE Partners AlixPartners Canaccord Genuity Group Inc NATS Rolls-Royce Hitachi Solutions British Land NatWest Group Legal & General London Stock Exchange Group CrowdStrike Lightsource bp GlaxoSmithKline plc